Aradigm
HomeAboutProductsTechnologiesInvestorsCareers
Press Releases

Press Releases

All Releases
Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2017 on February 13
Feb 09, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda , Ph.D., will present at the 19 th Annual BIO CEO & Investor Conference 2017 on Monday, February 13, 2017 , at 1:30 p.m. ET .
Aradigm to Present at 9th Annual Biotech Showcase Conference on January 9
Jan 06, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda , Ph.D., will present an overview of the Company at the 9 th Annual Biotech Showcase Conference on Monday, January 9, 2017 , at 5:00 p.m.
Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Lung Infections with Pseudomonas aeruginosa
Dec 01, 2016
Company to host conference call at 4:30 pm ET today HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ:ARDM) (the "Company") today announced top-line results from its two Phase 3 clinical trials (ORBIT-3 and ORBIT-4) evaluating the safety and efficacy of Pulmaquin®, the Company's
Aradigm to Present at the Stifel 2016 Healthcare Conference on November 16
Nov 10, 2016
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that Nancy Pecota , Aradigm's Chief Financial Officer, will present an overview of the Company at the Stifel 2016 Healthcare Conference at the Lotte New York Palace Hotel in New York, New York on
Aradigm Announces Third Quarter 2016 Financial Results
Nov 09, 2016
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation ( NASDAQ : ARDM) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2016 . Third Quarter 2016 Financial Results The Company recorded $50,000 in revenue in the third quarter of 2016
Multi-million Dollar DTRA Funding for Biodefense Research with Aradigm's Inhaled Ciprofloxacin
Oct 18, 2016
Liposomal Ciprofloxacin Being Developed as a Broad Spectrum Prophylaxis and Treatment for Multiple Bioterrorism Threats HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation ( NASDAQ : ARDM) ("Aradigm" or the "Company") announced today that the U.K.
Aradigm Announces Australian Research Council Funding to Develop Nanotechnologies Targeting Bacterial and Fungal Biofilms
Oct 07, 2016
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ:ARDM) (the "Company") today announced that it entered into an agreement with the University of Sydney to collaborate on a joint program on the development of advanced nanotechnologies for targeting bacterial and fungal biofilms that
Aradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis Patients
Sep 22, 2016
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ:ARDM) (the "Company") today announced that the last patient has completed the final dosing visit in the ORBIT-3 and ORBIT-4 Phase 3 clinical studies of Pulmaquin®, Aradigm's proprietary inhaled ciprofloxacin, an investigational new
Aradigm to Host Analyst Meeting and Webcast on September 26 in New York City
Sep 21, 2016
Event Will Feature Presentations by KOLs David Griffith, MD, and Gregory Tino , MD HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq: ARDM) (the "Company") announced today that it will host an Analyst Lunch on the topic of Non-Cystic Fibrosis Bronchiectasis (non-CF BE) on Monday,
Aradigm to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27
Sep 20, 2016
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) ("Aradigm" or the "Company") today announced that President and CEO, Igor Gonda , will present at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27, 2016 , at 1:00 p.m. ET .
Aradigm Announces Second Quarter 2016 Financial Results
Aug 10, 2016
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation ( NASDAQ : ARDM) (the "Company") today announced financial results for the second quarter and six months ended June 30, 2016 . Second Quarter 2016 Financial Results The Company recorded $14,000 in revenue in the second quarter of 2016 compared
Two Presentations on Aradigm's Inhaled Liposomal Ciprofloxacin Programs at the American Thoracic Society 2016 International Conference
May 11, 2016
HAYWARD, Calif. --(BUSINESS WIRE)-- The first presentation is co-authored by an international team of investigators and employees of Aradigm Corporation (NASDAQ:ARDM) (the "Company"); it discusses the details of the design of the ongoing Phase 3 clinical trials ORBIT-3 and ORBIT-4 investigating the
Aradigm Announces First Quarter 2016 Financial Results
May 10, 2016
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation ( NASDAQ : ARDM) (the "Company") today announced financial results for the first quarter and three months ended March 31, 2016 . Liquidity and Capital Resources On April 22, 2016 , the Company announced the pricing of $23 million of its senior
Aradigm Corporation Announces First Closing of Private Placement Offering of $23 Million Senior Convertible Notes Due 2021
Apr 26, 2016
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) ("Aradigm" or the "Company") announced today the first closing of its previously announced private placement of $23,000,000 aggregate principal amount of its senior convertible notes due 2021 (the "Notes") and related warrants to
Aradigm Corporation Prices Private Placement of Senior Notes
Apr 22, 2016
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) ("Aradigm" or the "Company") announced today the pricing of $23 million of its senior convertible notes due 2021 and related warrants to purchase 263,436 shares of the Company's common stock in a private placement conducted
Aradigm Announces Decision for Centralized Review of Pulmaquin by the European Medicines Agency
Mar 17, 2016
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that the European Medicines Agency (EMA) has approved its request to review Pulmaquin®, Aradigm's investigational inhaled liposomal ciprofloxacin product, under the Centralised Authorisation
Aradigm Announces Fourth Quarter 2015 and Full Year Financial Results
Mar 15, 2016
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ:ARDM) (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2015 . Fourth Quarter 2015 Results Since the Company has utilized the full amount of the $65 million of Grifols-funded
Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2016 on February 8
Feb 02, 2016
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda , Ph.D., will present at the 18 th Annual BIO CEO & Investor Conference 2016 on Monday, February 8, 2016 , at 10:30 a.m. ET .
Aradigm to Host Corporate Update Conference Call on January 6
Jan 05, 2016
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") will host a corporate update conference call at 9:00 am ET ( 6:00 am PT ) on Wednesday, January 6, 2016 . The Company will review recent progress with the Pulmaquin® investigational inhaled antibiotic program in
Aradigm Announces Third Quarter 2015 Financial Results
Nov 11, 2015
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2015 . Total revenue was $4.7 million for the third quarter of 2015, compared with $6.6 million in revenue for the third
Displaying 21 - 40 of 234
CONTACT NEWS & EVENTS LEGAL SITE MAP ©2018 Aradigm Corporation. All Rights Reserved.